Please login to the form below

Not currently logged in
Email:
Password:

warfarin

This page shows the latest warfarin news and features for those working in and with pharma, biotech and healthcare.

Xarelto no better than aspirin in secondary stroke study

Xarelto no better than aspirin in secondary stroke study

The overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin, but Xarelto has seen

Latest news

  • Xarelto beats aspirin for recurrent blood clots Xarelto beats aspirin for recurrent blood clots

    Meanwhile, the overall NOAC market is growing strongly in the face of a string of new studies showing the new drugs' benefits over older anticoagulants such as warfarin.

  • Bayer defends Xarelto as pivotal trial scrutinised Bayer defends Xarelto as pivotal trial scrutinised

    The trial used a device called INRatio, manufactured by Alere, to determine whether doses of warfarin should be adjusted to keep the drug in the right therapeutic range. ... The implication is that patients on warfarin may have been more prone to bleeds

  • Daiichi Sankyo licenses clot-busting antibody Daiichi Sankyo licenses clot-busting antibody

    Meanwhile, anticoagulants such as warfarin and the newer novel oral anticoagulant (NOAC) class can prevent clots from forming but are unable to dissolve them when already present.

  • NICE recommends Daiichi Sankyo's Lixiana for DVT and PE NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

    around £26, 000 per quality-adjusted life year (QALY), though it noted there are no definitive costs for warfarin monitoring. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better bleeding profile

  • Daiichi’s new anticoagulant recommended by NICE Daiichi’s new anticoagulant recommended by NICE

    warfarin that patients and physicians appreciate.”. ... The first OAC, which was approved more than 50 years ago, is the generic warfarin, but in recent years a spate of new drugs has come onto the market for AF

More from news
Approximately 2 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • Bringing about digital health change Bringing about digital health change

    Roche believes it is on to a winner with its CoaguChek system, developed in collaboration with QL, to help warfarin patients self monitor so they don't have to travel to

  • Pharma–payer partnerships – rhetoric or reality? Pharma–payer partnerships – rhetoric or reality?

    The class is likely to replace the current standard of care (warfarin) which has been around for over 50 years. ... Despite being considered a 'dirty' drug warfarin has spawned the development of complex blood monitoring clinics and associated medical

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Interestingly, a study published in Stroke in March 2012 found that dabigatran etexilate was a cost-effective

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics